RELATED CONTENT
September 6, 2016 — IBA (Ion Beam Applications S.A.) and RaySearch Laboratories have entered into a long-term strategic ...
September 06, 2016 
IBA (Ion Beam Applications S.A.) announced the first worldwide clinical implementation of its newly released Dolphin Online Ready Patient QA and Monitoring. The team at the Radiation Therapy department of the Klinikum Bayreuth GmbH in Bayreuth, Germany, has successfully validated and clinically implemented three Dolphin systems at two of their sites.
August 23, 2016 
IBA (Ion Beam Applications SA) has received U.S. Food and Drug Administration (FDA) clearance for its new super conducting accelerator, which is the latest development, essential to the ProteusONE compact Intensity Modulated Proton Therapy (IMPT) solution, that required approval from regulatory authorities.
August 18, 2016 Patient QA Efficiency with Dolphin presented at AAPM 2016 IBA booth. Dolphin Online Ready is released and in clinical ...
August 15, 2016 
IBA (Ion Beam Applications S.A.) and the Institute Curie in Paris, France, announced the signature of an agreement for the manufacturing, delivery, installation and maintenance of a new research beam line. This line will be connected to the existing beam transport line. This agreement also includes future research projects to be performed jointly by the two organizations over the coming 10 years.
July 05, 2016 
April 27, 2016 — IBA (Ion Beam Applications S.A.) announced the release of Dolphin Online Ready Patient QA and ...
April 27, 2016 Texas Center for Proton Therapy and IBA (Ion Beam Applications S.A.) announced the first patient treated in North America with the 360-degree Proteus Plus gantry.
April 19, 2016 
IBA (Ion Beam Applications SA) has recently received CE mark authorization of its new supra conducting accelerator.
April 05, 2016 
March 30, 2016 — IBA (Ion Beam Applications SA) announced it has signed a contract with the University Hospitals Leuven ...
March 30, 2016 
IBA (Ion Beam Applications S.A.) announced the sale of IBA Molecular (IBAM) in which IBA had a 40 percent stake, to funds advised by CapVest Partners LP (“CapVest”), has closed successfully.
March 29, 2016